Skip to main content
Equibles
MEDP logo

MEDP · Medpace Holdings, Inc.

Track MEDP — free

Use MEDP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$653.94 -2.90 (-0.44%) At close · Nov 13
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$18.29B
Shares
27.97M
Volume · Nov 13 105.55K Avg daily vol (3M) 256.16K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$653.94 Open$660.25 Day$644.77–660.25 52W close$393.42–692.68 Avg vol 30d288K Short int1.4M · 4.9% of shares · 3.5d Short vol63% Last earningsOct 22, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 22

Up next

Next earnings call
Feb 9, 2027 Est · unconfirmed · in 12 wks
Q3 2026 earnings call transcript
call held Oct 22, 2026
Play latest call

Latest documents

2026
Oct 22
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Medpace reported nine-month revenue of $2,129.9 million, net income of $382.7 million and operating cash flow of $530.4 million for the period ended September 30, 2026. Backlog reached $3,167.2 million, and the Board authorized up to $1.0 billion in share repurchases.

Revenue $716M ▲ 8.5% Net income $137.46M ▲ 23.7% Diluted EPS $4.84 ▲ 25.4%
Read from the MD&A section
Oct 22
Earnings call
Q3 2026 earnings call

MedPACE reported third quarter 2026 revenue of $716 million, up 8.5%, net new business awards of $873.4 million, and a $1 billion share repurchase authorization; full-year revenue guidance is $2.835 billion to $2.855 billion, with 2027 guidance planned for February.

Oct 21
Current report 8-K Events of Oct 20
Financial results, Other events

Medpace Holdings, Inc. reported third-quarter 2026 revenue of $716.0 million, up 8.5%, and GAAP net income of $137.5 million, or $4.84 per diluted share. The board authorized up to $1.0 billion of share repurchases through December 31, 2028.

Jul 23
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $707.33M ▲ 17.2% Net income $121.36M ▲ 34.5% Diluted EPS $4.25 ▲ 37.1%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.84B
Trailing 12 months
Net income (TTM)
$517.83M
Trailing 12 months
Revenue growth YoY
+8.5%
Year over year
Operating margin
21.4%
Trailing 12 months
P / E (TTM)
36.3
Trailing earnings · reciprocal yield 2.8%
FCF yield
3.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$705.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.5%
Year over year · fewer shares
Price change (1Y)
+10.6%
Trailing year
Short interest
4.9%
Latest settlement · 3.5 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲7.7% $536.59M $117.02M '24 Q4* ▲9.3% $558.57M $114.59M '25 Q1 ▲14.2% $603.31M $90.26M '25 Q2 ▲23.7% $659.90M $111.14M '25 Q3 ▲32% $708.45M $135.13M '25 Q4* ▲26.5% $706.60M $123.87M '26 Q1 ▲17.2% $707.33M $121.36M '26 Q2 LATEST ▲8.5% $716.00M $137.46M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +23%
above
Price vs 50-day avg +4%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 87%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +52%
trailing
YTD return +16%
this year
Relative strength +52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $630 › 200d $532 — 50d above 200d
Institutional flow Distributing
662 of 706 funds reported for Sep 30 · net -487.1K sh shares · +91 new
Insider flow Distributing
Net -$191.8M over 90 days · 100% sells
Short interest Falling
4.95% of shares out · ▼ -14.1% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
706 holders — mid 3-yr range
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +20%
Y/Y
EPS growth +21%
Y/Y
Free cash flow $681.9M
Valuation P/E 36.3
in line
Buyback $1.0B
authorized
Balance sheet $497.0M
net cash
Quant / Vol
risk profile
Moderate
Volatility 44%
annualized · 1-yr
Max drawdown −37%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Oct 21, 2026
2026
Revenue Maintained $2.84B – $2.86B
Jul 23, 2026 $2.81B – $2.89B changed to Oct 21, 2026 $2.84B – $2.86B
prior FY $2.53B midpoint +12.4% Y/Y
Growth 12% – 12.8%
full year 2026
GAAP net income Raised $514M – $524M
Apr 22, 2026 $487M – $511M changed to Oct 21, 2026 $514M – $524M
EBITDA Raised $638M – $652M
Jul 22, 2026 $618M – $642M changed to Oct 21, 2026 $638M – $652M
Diluted earnings per share (GAAP) Raised $17.97 – $18.32
Jul 23, 2026 $17.25 – $17.95 changed to Oct 21, 2026 $17.97 – $18.32
prior FY $15.28 midpoint +18.8% Y/Y
Tax rate 19% – 19.5%
Interest income $22.9M
Previous outlook earlier release · from the Earnings Call filed Jul 23, 2026

Still-open targets the latest release did not restate under the same label.

EBITDA · 2026 $618M – $642M
Direct service costs as a percentage of revenue · Q3 and Q4 41% – 42%
Guided vs delivered · last 8 settled
Total revenue full year 2025
guided $2.48B – $2.53B
$2.53B Beat +1.0%
Earnings per diluted share full year 2025
guided $14.60 – $14.86
$15.28 Beat +3.7%
Revenue full year 2024
guided $2.13B – $2.18B
$2.11B Miss −1.9%
Diluted earnings per share (GAAP) full year 2024
guided $11.24 – $11.93
$12.63 Beat +9.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+23% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
87% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $630 › 200d $532 — 50d above 200d
Institutional flow Distributing
662 of 706 funds reported for Sep 30 · net -487.1K sh shares · +91 new
Insider flow Distributing
Net -$191.8M over 90 days · 100% sells
Short interest Falling
4.95% of shares out · ▼ -14.1% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
706 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $393 Now $654 · 87% Range high $693
vs 200-day avg +23% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Net new business awards 795.7M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MEDP
Medpace Holdings, Inc.
this stock
$18.29B +16.4% +20.0% 36.3 4.9%
TMO
Thermo Fisher Scientific Inc.
 $259.44B +20.8% +14.5% 36.9 1.3%
DHR
Danaher Corp
 $163.94B +1.8% +8.5% 38.1 1.2%
IDXX
Idexx Laboratories Inc
 $55.48B +4.1% +10.4% 47.5 3.0%
A
Agilent Technologies, Inc.
 $49.04B +27.8% +6.4% 34.2 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
759
% held
87.2%
Reported
662 of 706
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
577
View
Short & Settlement
Short Interest Falling
Shares short
1.4M
Days to cover
3.5d
Change
-228.1K sh
View
Short Volume
Short vol %
63%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
33
Value
$19.9K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
49.6%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$191.8M
Buyers / Sellers
0 / 7
Buyers Sellers
View
Congressional Trades Buy
Member
David J. Taylor
Amount
$1.0K–$15.0K
Traded
May 15, 2026
View
Financials
Financials
Revenue (FY)
$2.5B
Net income (FY)
$451.1M
EPS diluted
$15.28
View
Buybacks
Authorized
$1.0B
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 22, 2026
This year
15

Medpace reported nine-month revenue of $2,129.9 million, net income of $382.7 million and operating cash flow of $530.4 million for the period ended September 30, 2026. Backlog reached $3,167.2 million, and the Board authorized up to $1.0 billion in share repurchases.

View
Proposed Sales
Value
$859.1K
Shares
1.2K
Filed
Oct 29, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 22, 2026
View
Investor Relations
Latest news
Medpace Holdings, Inc. Reports Th…
Published
Oct 21, 2026
View

Performance

5D 20D 120D MTD YTD
MEDP +0.1% +5.7% +52.4% +0.3% +16.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.5% +6.9% +51.9% +0.5% +5.8%

Capital returns

Buyback program · as of Oct 20, 2026
Authorized
$1.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1668397 CUSIP 58506Q109 13F (30d) 609 filings 561 filers Visit website Investor relations